An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non-Muscle-Invasive Bladder Cancer

European Urology

Volumn 56, Issue 2, 2009, Pages 247-256

  Malmström, Per Uno ^a   Sylvester, Richard J ^b   Crawford, David E ^c   Friedrich, Martin ^d   Krege, Susanne ^e   Rintala, Erkki ^f   Solsona, Eduardo ^g   Di Stasi, Savino M ^h   Witjes, J Alfred ⁱ  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF COLORADO   (United States)

^d HELIOS KLINIKUM KREFELD   (Germany)

^e Krankenhaus Maria Hilf GmbH   (Germany)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Bacillus Calmette Gu rin; Bladder neoplasms; Instillation therapy; Meta analysis; Mitomycin C

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; HUMANS; MITOMYCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 67649431728     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.04.038     Document Type: Article

References (21)

1. Coley W. The treatment of cancer. Guy's Hosp Gaz 26 (1911) 7-14
2. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156 (1996) 1934-1940
3. Shelley M.D., Kynaston H., Court J., et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88 (2001) 209-216
4. Han R.F., and Pan J.G. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67 (2006) 1216-1223
5. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
6. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
7. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-686
8. Shelley M.D., Wilt T.J., Court J., et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
9. Huncharek M., and Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol 26 (2003) 402-407
10. Krege S., Giani G., Meyer R., et al. A randomised multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral restion plus bacillus Calmette-Guerin. J Urol 156 (1996) 962-966
11. Lamm D.L., Blumenstein B.A., Crawford D., et al. Randomised intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol 1 (1995) 119-126
12. Malmström P.-U., Wijkström H., Lundholm C., et al. 5-year follow-up of a randomised prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 161 (1999) 1124-1127
13. Rintala E., Jauhiainen K., Alfthan O., et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol 20 (1991) 19-25
14. Witjes J.A., van der Meijden A.P.M., Collette L., et al. Long-term follow-up of an EORTC randomised prospective trial comparing intravesical bacille Calmette-Guerin and mitomycin C in superficial bladder cancer. Urology 52 (1998) 403-410
15. Witjes W.P.J., Witjes A., Oosterhof G.O.N., Debruyne F.M.J., and Dutch South East Cooperative Urological Group. Update on the Dutch Cooperative Trial: mitomycin C versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTa-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Semin Urol Oncol 14 (1996) 10-16
16. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
17. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
18. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomised study. J Urol 170 (2003) 777-782
19. Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci 703 (1993) 156-163
20. Cookson M.S., Herr H.W., Zhang Z.F., Soloway S., Sogani P.C., and Fair W.R. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158 (1997) 62-67
21. Lambert E.H., Pierorazio P.M., Olsson C.A., Benson M.C., McKiernan J.M., and Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100 (2007) 33-36